PDCD1 and lung carcinoma: Besides, we identified pemetrexed, the only drug currently approved by the FDA for first-line use in combination with anti-PD1 antibodies against lung cancer regardless of PD-L1 expression [7,8,9], which indicated that our finding drugs may enrich the library of candidates for combination strategies based on immune checkpoint inhibitors.